{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:55:56Z","timestamp":1776664556693,"version":"3.51.2"},"reference-count":12,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":108,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Case Reports in Infectious Diseases"],"published-print":{"date-parts":[[2026,1]]},"abstract":"\n Background<\/jats:title>\n Linezolid is an oxazolidinone antibiotic used in the treatment of Gram\u2010positive bacterial infections. However, its prolonged use is often limited by adverse effects, including thrombocytopenia. Therapeutic drug monitoring (TDM) has been proposed to individualize linezolid dosing to mitigate such adverse effects. This study presents a case of linezolid\u2010induced thrombocytopenia successfully managed with TDM and dose individualization in a patient receiving linezolid as chronic suppressive therapy for cardiac implantable electronic device (CIED) infection.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A 92\u2010year\u2010old female with a history of recurrent\n Corynebacterium striatum<\/jats:italic>\n bacteremia and complex cardiovascular conditions who completed a six\u2010week course of intravenous therapy and were placed on chronic suppressive therapy with oral linezolid. Given the risk of thrombocytopenia, TDM was utilized to guide linezolid dosing. Platelet counts and linezolid trough levels were regularly monitored, and dose adjustments were made accordingly.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Upon initiation of linezolid (600\u2009mg daily), the patient\u2019s baseline platelet count was 150\u2009\u00d7\u200910\n 9<\/jats:sup>\n \/L. On day 19, platelet counts declined to 73\u2009\u00d7\u200910\n 9<\/jats:sup>\n \/L. Linezolid was temporarily withheld, and TDM revealed a supratherapeutic trough level of 10.26\u2009mcg\/mL. The dosage was adjusted to 300\u2009mg once daily, leading to the stabilization of platelet counts at 140\u2009\u00d7\u200910\n 9<\/jats:sup>\n \/L. Subsequent monitoring showed a trough level within the target range (7.62\u2009mcg\/mL) with no further episodes of thrombocytopenia or additional adverse effects out to day 172.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This case highlights the utility of TDM in managing linezolid\u2010induced thrombocytopenia, particularly in patients requiring prolonged therapy. TDM enabled precise dose adjustments, ensuring therapeutic efficacy while minimizing toxicity. The findings support the broader implementation of TDM in linezolid therapy to enhance patient safety and treatment outcomes, particularly in long\u2010term therapy or deep\u2010seated infections.<\/jats:p>\n <\/jats:sec>","DOI":"10.1155\/crdi\/3214119","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:27:36Z","timestamp":1776662856000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond \u2018One Size Fits All\u2019: Abatement of Linezolid\u2010Induced Thrombocytopenia Through Therapeutic Drug Monitoring and Precision Dosing\u2014A Case Study"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2803-9704","authenticated-orcid":false,"given":"Kennedy C.","family":"Concannon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Gullickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9441-0283","authenticated-orcid":false,"given":"Daniel C.","family":"DeSimone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-5544","authenticated-orcid":false,"given":"Omar Abu","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-8347","authenticated-orcid":false,"given":"Tanner M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5050-6689","authenticated-orcid":false,"given":"Ryan W.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-0978","authenticated-orcid":false,"given":"Josh","family":"Clement","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"e_1_2_9_1_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.967311"},{"key":"e_1_2_9_2_2","unstructured":"Prescribing Information Linezolid. Accessdata.fda.gov 2013."},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12797"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01885-13"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03542-z"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12806"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.05.010"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.08.023"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106783"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz374"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks153"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-024-00458-6"}],"container-title":["Case Reports in Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crdi\/3214119","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/crdi\/3214119","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crdi\/3214119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:27:38Z","timestamp":1776662858000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/crdi\/3214119"}},"subtitle":[],"editor":[{"given":"Rajib","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/crdi\/3214119"],"URL":"https:\/\/doi.org\/10.1155\/crdi\/3214119","archive":["Portico"],"relation":{},"ISSN":["2090-6625","2090-6633"],"issn-type":[{"value":"2090-6625","type":"print"},{"value":"2090-6633","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2024-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"3214119"}}